Vendor comparison · 2026
Orforglipron vendors: 0 compared on COAs and price
MetabolicAlso known as LY3502970, OWL833
Evidence tier
Moderate published literature
132 publications over 6 years · trials not yet curated
- Vendors carrying it
- 0
- 0 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- —
- Publications located
- 132
- researched since 2020
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Orforglipron certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. No vendor price for Orforglipron is on record. 0 vendors carrying Orforglipron are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Orforglipron
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| No indexed vendor currently lists this compound. | |||||||||
Independent assays
No independently commissioned assay of Orforglipron is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Orforglipron names a laboratory this index could identify.
Every certificate record
No certificate record for Orforglipron is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2020 — 6 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
132 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Orforglipron?
An orally available, non-peptide small-molecule GLP-1 receptor agonist in late-stage clinical development for type 2 diabetes and obesity.
Studied in published research for type 2 diabetes and obesity, as an oral GLP-1 agonist.
Regulatory status
Orforglipron is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity — The New England journal of medicine (2023)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2023).
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants — Diabetes, obesity & metabolism (2023)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2023).
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment — The New England journal of medicine (2025)
Peer-reviewed article indexed in PubMed, published in The New England journal of medicine (2025).
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes — Diabetes, obesity & metabolism (2023)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2023).
- Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants — Clinical pharmacology in drug development (2026)
Peer-reviewed article indexed in PubMed, published in Clinical pharmacology in drug development (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.